Mirum Pharmaceuticals (FRA:08D) Price-to-Tangible-Book : (As of Jun. 09, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-06-09), Mirum Pharmaceuticals's share price is €22.80. Mirum Pharmaceuticals's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was €-0.45. Hence, Mirum Pharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Mirum Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 6 years, Mirum Pharmaceuticals's highest Price to Tangible Book Ratio was 136.80. The lowest was 1.55. And the median was 5.47.

FRA:08D's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.77
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Mirum Pharmaceuticals's share price is €22.80. Mirum Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2024 was €4.59. Hence, Mirum Pharmaceuticals's P/B Ratio of today is 4.97.

Mirum Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Mirum Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Price-to-Tangible-Book Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.64

8.39

Mirum Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															10.14	41.87	137.04	-	-

Competitive Comparison of Mirum Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Mirum Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Price-to-Tangible-Book falls into.

Mirum Pharmaceuticals Price-to-Tangible-Book Calculation

Mirum Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	22.80	/	-0.447
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Mirum Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (FRA:08D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

MIRM:USA MIRM:Mexico

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines